BR0111182A - Peptìdeos neuroprotetores - Google Patents

Peptìdeos neuroprotetores

Info

Publication number
BR0111182A
BR0111182A BR0111182-5A BR0111182A BR0111182A BR 0111182 A BR0111182 A BR 0111182A BR 0111182 A BR0111182 A BR 0111182A BR 0111182 A BR0111182 A BR 0111182A
Authority
BR
Brazil
Prior art keywords
erythropoietin
peptides
activity
human erythropoietin
therapeutic
Prior art date
Application number
BR0111182-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Virginia Smith-Swintosky
Michael Renzi
Carlos Plata-Salaman
Linda Jolliffe
Francis Farrell
Dana L Johnson
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22771463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0111182(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of BR0111182A publication Critical patent/BR0111182A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
BR0111182-5A 2000-05-26 2001-05-23 Peptìdeos neuroprotetores BR0111182A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20765400P 2000-05-26 2000-05-26
PCT/US2001/016654 WO2001091780A1 (en) 2000-05-26 2001-05-23 Neuroprotective peptides

Publications (1)

Publication Number Publication Date
BR0111182A true BR0111182A (pt) 2004-02-25

Family

ID=22771463

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111182-5A BR0111182A (pt) 2000-05-26 2001-05-23 Peptìdeos neuroprotetores

Country Status (11)

Country Link
EP (1) EP1296702A4 (https=)
JP (1) JP2003534384A (https=)
CN (1) CN1318084C (https=)
AU (2) AU7490401A (https=)
BR (1) BR0111182A (https=)
CA (1) CA2410453A1 (https=)
IL (1) IL153079A0 (https=)
MX (1) MXPA02011727A (https=)
NZ (1) NZ522924A (https=)
WO (1) WO2001091780A1 (https=)
ZA (1) ZA200210304B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2376232A1 (en) 1999-06-14 2000-12-21 Genentech, Inc. A structured peptide scaffold for displaying turn libraries on phage
US20030166003A1 (en) * 1999-06-14 2003-09-04 Cochran Andrea G. Structured peptide scaffold for displaying turn libraries on phage
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
US6914123B2 (en) 2001-04-17 2005-07-05 Genentech, Inc. Hairpin peptides with a novel structural motif and methods relating thereto
PT1624891E (pt) 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
JP2007530440A (ja) * 2003-05-12 2007-11-01 アフィーマックス・インコーポレイテッド 新規ポリ（エチレングリコール）修飾化合物およびその用途
SI1625156T1 (sl) 2003-05-12 2013-02-28 Affymax, Inc. Peptidi, ki se veĹľejo k eritropoetinskemu receptorju
WO2004100997A2 (en) 2003-05-12 2004-11-25 Affymax, Inc. Spacer moiety for poly(ethylene glycol) -modified peptides
JP4266028B2 (ja) * 2003-05-12 2009-05-20 アフィーマックス・インコーポレイテッド エリスロポエチン受容体に結合する新規ペプチド
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
EP1848461A2 (en) 2005-02-16 2007-10-31 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EP1857463A1 (en) * 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
EP3669894A3 (en) 2006-06-30 2020-08-26 Syntab Therapeutics GmbH Novel multifunctional compounds for pharmaceutical purposes
US8106154B2 (en) 2007-01-31 2012-01-31 Affymax, Inc. Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
EP2018835B1 (de) 2007-07-09 2014-03-05 Augustinus Bader Wirkstoff abgebendes Pflaster
WO2009094172A2 (en) * 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CN102365021B (zh) 2009-02-05 2015-07-15 伊缪诺金公司 新型苯并二氮杂*衍生物
RU2410392C2 (ru) * 2009-02-16 2011-01-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН Дипептидные миметики нейротрофинов ngf и bdnf
EP2590666B1 (en) 2010-07-06 2017-04-26 Augustinus Bader Topical application of erythropoietin for use in the treatment of injuries of the cornea
JP6049642B2 (ja) * 2011-02-15 2016-12-21 イミュノジェン・インコーポレーテッド 複合体の調製方法
HK1223298A1 (zh) * 2013-07-17 2017-07-28 阿拉伊姆药品公司 预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物
CN105017406B (zh) * 2014-04-21 2020-10-09 上海市第一人民医院 一类新的具有神经保护功能的多肽
CN105233256A (zh) * 2015-10-28 2016-01-13 中国人民解放军第三军医大学 促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用
GB201609083D0 (en) 2016-05-24 2016-07-06 Syntab Therapeutics Gmbh Synthetic compound
US12024571B2 (en) 2018-09-14 2024-07-02 Epo-Med Inc. Anti-erythropoietin receptor peptide
WO2025262329A1 (en) 2024-06-21 2025-12-26 Syntab Therapeutics Gmbh Synthetic molecules comprising tlr2 ligands

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US6165783A (en) * 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents

Also Published As

Publication number Publication date
EP1296702A1 (en) 2003-04-02
NZ522924A (en) 2004-12-24
MXPA02011727A (es) 2003-10-24
CN1318084C (zh) 2007-05-30
CN1452492A (zh) 2003-10-29
IL153079A0 (en) 2003-06-24
JP2003534384A (ja) 2003-11-18
AU2001274904B2 (en) 2006-08-31
AU7490401A (en) 2001-12-11
HK1058484A1 (zh) 2004-05-21
CA2410453A1 (en) 2001-12-06
WO2001091780A1 (en) 2001-12-06
EP1296702A4 (en) 2005-05-11
ZA200210304B (en) 2004-03-19

Similar Documents

Publication Publication Date Title
BR0111182A (pt) Peptìdeos neuroprotetores
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
ATE446365T1 (de) Menschliches fgf-21 gen und genexpressionsprodukte
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
CY1107533T1 (el) Επιλεκτικοι συναγωνιστες και ανταγωνιστες της il-2
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DK1151009T3 (da) Antimikrobielt/endotoksin-neutraliserende polypeptid
PT698108E (pt) Vectores adenovirais de origem animal e utilizacao em terapia genica
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
ATE386808T1 (de) Arzneimittelzubereitungen für die behandlung von alpha-galactosidase a-mangel
BR9714677A (pt) "enantiÈmeros 3-piridila e seu uso como analgésicos"
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
WO2002029087A3 (en) Use of lymphangiogenic agents to treat lymphatic disorders
DE69835680D1 (de) Therapeutische verwendung von smr1 protein und seinen aktiven derivaten
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
SE0102147D0 (sv) New methods
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
BR0112131A (pt) Composições farmacêuticas e métodos para uso
DE60035192D1 (de) Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung
BR0210578A (pt) Remédios para doenças eosinofìlicas
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
DE69314586D1 (de) Arzneimittelzusammensetzung enthaltend TCF-II
AP2034A (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof.
PT1032402E (pt) Uso de citicolina para o tratamento de esclerose multipla

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: JOHNSON & JOHNSON (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]